Payment overview · 2025
General Payments
$41.08
2 reported records · 2 companies
Healthcare provider profile · identity verified
Gerard Brophy Chamberlin, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MESA, AZ · NPI 1750503124
Verified facts
What the public records show
CMS Open Payments records show Gerard Brophy Chamberlin, MD received $41.08 in general payments during 2025 across 2 reported records.
Astellas Pharma US Inc accounted for 51.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Myrbetriq by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.10 | 51.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.98 | 48.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $21.10 | 1 |
| Long term medical supply or device loan | $19.98 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE INSULINX Normalized: freestyle insulinx |
Device | Abbott Laboratories | $19.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
49 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 956 | 281 |
| Levothyroxine Sodium | Levothyroxine Sodium | 611 | 172 |
| Losartan Potassium | Losartan Potassium | 485 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 482 | 144 |
| Lisinopril | Lisinopril | 463 | 139 |
| Omeprazole | Omeprazole | 331 | 111 |
| Metformin Hcl | Metformin Hcl | 327 | 102 |
| Pantoprazole Sodium | Pantoprazole Sodium | 307 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 290 | 89 |
| Montelukast Sodium | Montelukast Sodium | 288 | 86 |
| Gabapentin | Gabapentin | 280 | 92 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 260 | 99 |
| Trazodone Hcl | Trazodone Hcl | 254 | 83 |
| Tamsulosin Hcl | Tamsulosin Hcl | 248 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 218 | 72 |
| Furosemide | Furosemide | 201 | 75 |
| Potassium Chloride | Potassium Chloride | 193 | 62 |
| Simvastatin | Simvastatin | 186 | 55 |
| Fluoxetine Hcl | Fluoxetine Hcl | 175 | 57 |
| Ezetimibe | Ezetimibe | 168 | 48 |
| Eliquis | Apixaban | 153 | 48 |
| Allopurinol | Allopurinol | 152 | 51 |
| Hydralazine Hcl | Hydralazine Hcl | 149 | 44 |
| Alendronate Sodium | Alendronate Sodium | 148 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 56 |
| Meloxicam | Meloxicam | 136 | 40 |
| Carvedilol | Carvedilol | 134 | 39 |
| Warfarin Sodium | Warfarin Sodium | 131 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 130 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 47 |
| Prednisone | Prednisone | 120 | 68 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 32 |
| Ozempic | Semaglutide | 110 | 30 |
| Spironolactone | Spironolactone | 110 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 105 | 29 |
| Tramadol Hcl | Tramadol Hcl | 105 | 44 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 98 | 98 |
| Celecoxib | Celecoxib | 95 | 27 |
| Jardiance | Empagliflozin | 89 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 26 |
| Alprazolam | Alprazolam | 87 | 42 |
| Sertraline Hcl | Sertraline Hcl | 85 | 21 |
| Finasteride | Finasteride | 84 | 26 |
| Glimepiride | Glimepiride | 78 | 19 |
| Midodrine Hcl | Midodrine Hcl | 78 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 30 |
| Donepezil Hcl | Donepezil Hcl | 70 | 20 |
| Bupropion Xl | Bupropion Hcl | 69 | 23 |
| Ibuprofen | Ibuprofen | 65 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 19 |
| Farxiga | Dapagliflozin Propanediol | 61 | 14 |
| Famotidine | Famotidine | 60 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | 15 |
| Valsartan | Valsartan | 51 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 21 |
| Lorazepam | Lorazepam | 49 | suppressed |
| Myrbetriq | Mirabegron | 49 | 21 |
| Estradiol | Estradiol | 48 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 14 |
| Primidone | Primidone | 46 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | suppressed |
| Synthroid | Levothyroxine Sodium | 45 | 13 |
| Glipizide | Glipizide | 44 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 44 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 43 | 14 |
| Mirtazapine | Mirtazapine | 42 | suppressed |
| Naproxen | Naproxen | 41 | 20 |
| Chlorthalidone | Chlorthalidone | 39 | suppressed |
| Gemfibrozil | Gemfibrozil | 39 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 15 |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 20 |
| Atenolol | Atenolol | 36 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 36 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | suppressed |
| Clonazepam | Clonazepam | 34 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Mupirocin | Mupirocin | 32 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | 11 |
| Pregabalin | Pregabalin | 32 | 20 |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Azithromycin | Azithromycin | 27 | 22 |
| Baclofen | Baclofen | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 18 |
| Calcitriol | Calcitriol | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 12 |
| Fluconazole | Fluconazole | 23 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | 13 |
| Trulicity | Dulaglutide | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Rybelsus | Semaglutide | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Linzess | Linaclotide | 20 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | 18 |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Praluent Pen | Alirocumab | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Nexletol | Bempedoic Acid | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 12 |
| Ondansetron Odt | Ondansetron | 17 | 11 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 13 |
| Febuxostat | Febuxostat | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Xtampza Er | Oxycodone Myristate | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $41.08 · 2 records | Astellas Pharma US Inc | FREESTYLE INSULINX, Veozah | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error